For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.
Tumour-Induced Hypercalcaemia (TIH)
This is an international site for Zometa® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
ZOMETA is approved for use in the following countries: Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cuba, Curacao, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Korea, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Malta, Mexico, Moldova, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Peru, Philippines, Poland, Portugal, Qatar, Republic Srpska, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Syria, Taiwan, Thailand, The Netherlands, Trinidad and Tobago, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, Uzbekistan, Venezuela.
Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.
ZOMETA International Website
This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)
For patients with TIH, the recommended ZOMETA dose is 4 mg1
ZOMETA 4 mg in 100 mL of calcium-free infusion solution should be infused over no less than 15 minutes1
Hydration is key when treating TIH with ZOMETA1,2
Because TIH causes severe fluid imbalances, maintaining proper hydration during treatment is critical2
Patients must be assessed before administration of ZOMETA to ensure they are adequately hydrated1
Vigorous saline hydration should be employed to bring urine output to approximately 2 L/day3
Overhydration should be avoided in patients at risk for cardiac failure1
Assess renal function prior to treatment in patients with TIH1
The risks and benefits of ZOMETA therapy should be evaluated in patients with TIH who have severe renal impairment1
No dose adjustment is necessary in patients with serum creatinine <400 μmol/L or <4.5 mg/dL1
Patients with higher serum creatinine levels were not included in clinical studies of ZOMETA in TIH
References:1. ZOMETA Summary of Product Characteristics. Novartis Pharma AG. 2. Major P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist. 2002;7:481-491. 3. ZOMETA US Prescribing Information. Novartis Pharmaceuticals Corporation.
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
Italiano
Français
Español
Deutsch
English
